0XA1 Study This study will test if an investigational medicine (a Medicine being studied) could safely reduce weight in people with obesity or overweight. Inclusion Criteria: Aged 18 to 75 years old Do NOT have diabetes have obesity (BMI of 30 or more) or have overweight (BMI of 27 or more) and a health condition: […]
CogMS – A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis The present study will investigate the correlation between objective and subjective cognition in multiple sclerosis. The study will also investigate the impact of covariates such as fatigue and depression, the relationship with the Expanded Disability Status Scale (EDSS) and brain volumetrics as
Generation HD-2 This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with a placebo in participants with prodromal and early manifest Huntington’s Disease. Inclusion Criteria: Visit link below for more info: Ages Eligible for Study: 25 Years to 50 Years (Adult) Sexes Eligible for Study: All Generation HD-2 Link
ENVISION Trial The objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer’s disease. What is Alzheimer’s Disease? Alzheimer’s is
PROSEEK To Potentially Help Slow Progression for People with Early-stage Parkinson’s Disease The PROSEEK Study is a clinical research study evaluating a once-daily investigational drug for people with early-stage Parkinson’s disease (PD). The investigational drug is being studied to see if it can slow the progression of Parkinson’s disease. It is designed to block a
Testing the hypothesis that treatment with NRX-101 is superior to standard of care (lurasidone) in improving symptoms of depression as measured by the total Montgomery Åsberg Depression Rating Scale (MADRS-10) score in patients with bipolar depression and subacute suicidal ideation and behavior (SSIB) which does not require hospitalization.
ADNI4 Trial The ADNI4 is multi-center, a non-randomized, natural history, non-treatment study. 1,150 participants will be enrolled across three cohorts: cognitively normal (CN), mild cognitive impairment (MCI) and dementia (DEM). Participants between the ages of 55-90 (inclusive) will be enrolled at 59 sites in the United States and Canada. Approximately, 750 participants will be newly
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
ADNI3 Trial Dent is taking part in an observational study called the ADNI3 Trial. This historic study of brain aging could help change the future of Alzheimer’s disease. We are looking for volunteers between 55 and 90 years of age to participate in the ADNI3 trial. Poor memory is often viewed as a simple sign
A 30-year-old female presented to Dr. Lixin Zhang at Dent Neurologic’s Dizziness, Balance, and Tinnitus Center with a complaint of headaches and dizziness. Three months ago she had her first vertigo attack; she felt like the room was spinning and got nauseous. Since then, she’s had five more of these major attacks each lasting over
The connection between dizziness (vertigo) & migraine history Read More »
